| Product |
Hyper-Immune Plasma Yield
|
|---|---|
| Description of Project |
Plasma Technologies was contracted to develop and optimize a process to produce higher yielding anti-COVID-19 immune serum for scale-up and manufacturing. |
| Unique Impact |
If successful, a higher yield hyperimmune serum would be an improvement over the current standard method. Convalescent plasma, which is collected from a person who has recovered from a disease, may be beneficial in the treatment of patients suffering from COVID-19. |
| Base Award Amount |
$741,925.00
|
| Category |
Therapeutics Supplies and Raw Materials
|
Official websites use .gov
A .gov website belongs to an official government organization in the United
States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely
connected to the .gov website. Share sensitive information only on official, secure websites.
